Fri, October 19, 2012
Thu, October 18, 2012
Wed, October 17, 2012
Tue, October 16, 2012
Mon, October 15, 2012
Sun, October 14, 2012
Fri, October 12, 2012
Thu, October 11, 2012
Wed, October 10, 2012
Tue, October 9, 2012
Mon, October 8, 2012
Sun, October 7, 2012
Sat, October 6, 2012
Fri, October 5, 2012
Thu, October 4, 2012
Wed, October 3, 2012
Tue, October 2, 2012
Mon, October 1, 2012

Trellis and OMT Announce Therapeutic Antibody Discovery Collaboration


//health-fitness.news-articles.net/content/2012/ .. herapeutic-antibody-discovery-collaboration.html
Published in Health and Fitness on Monday, October 8th 2012 at 6:15 GMT by Market Wire   Print publication without navigation


SOUTH SAN FRANCISCO, Calif. & PALO ALTO, Calif.--([ ])--Trellis Bioscience LLC (Trellis) and Open Monoclonal Technology, Inc. (OMT) today announced a new collaboration where the companies will join forces to generate human antibodies against therapeutic targets identified by Trellis and its partners using OMTas OmniRata" platform. Trellis will apply its CellSpota" antibody screening technology to libraries of OmniRat-generated B cells to discover high affinity, ultra rare antibodies with precisely defined specificity. Trellis will advance and partner each program and share the deal economics with OMT depending on the stage of development.

"We are pleased to collaborate with Trellis to capture the synergies of our complementary antibody discovery technologies. This collaboration further illustrates OMTas ability to partner with a range of companies to produce human therapeutic antibodies."

Stote Ellsworth, Trellis CEO and President, said: aTrellisa CellSpot platform has shown in four consecutive programs the unique ability to mine rare, best-in-class therapeutic antibodies directly from human blood. In addition to our native human approach, the collaboration with OMT will leverage Trellisa powerful multiplexed screening in the context of antibody libraries generated with the OmniRat platform. This will allow Trellis to expand into new therapeutic areas and expand its commercial opportunities, particularly in the field of cancer.a

Dr. Roland Buelow, OMT CEO and Founder, continued: "We are pleased to collaborate with Trellis to capture the synergies of our complementary antibody discovery technologies. This collaboration further illustrates OMTas ability to partner with a range of companies to produce human therapeutic antibodies.a

About Trellis Bioscience LLC

Trellis is a venture funded therapeutic antibody company formed around a breakthrough, high throughput discovery platform capable of isolating ultra-rare therapeutic-grade antibodies directly from the blood of humans and other mammals, and from other antibody library sources including hybridomas. Trellisa CellSpot technology has generated a robust pipeline of early-stage programs targeting respiratory syncytial virus (RSV), cytomegalovirus (CMV), influenza, methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus A (GAS) and cancer.

Open Monoclonal Technology, Inc. a" anaturally optimized human antibodiesa"a

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for development of human therapeutic antibodies. OMT has developed OmniRata", the first fully human monoclonal antibody platform using transgenic rats. OmniRat is based on an improved understanding of B cell development and a novel approach to inactivation of endogenous antibody expression. These transgenic animals make antibodies as efficiently as wild type animals. OmniRat is a new and proprietary technology with unrestricted development options for fully human monoclonal antibodies for all targets and indications worldwide.


Publication Contributing Sources